Gila Therapeutics is pioneering an entirely novel means of delivering natural peptide hormones through topical lingual signalling mechanisms Focused on bringing multiple peptide hormones through clinical phases for novel treatment of obesity and associated metabolic disorders.

Obesity, Type 2 Diabetes
and
Metabolic Disorder Crisis

Gila Topical Lingual Neural Signaling enables delivery of natural peptide hormones with the goal of activating targeted areas of the brain directly implicated in regulating metabolism.
Gila’s lead program is Topical Lingual PYY. The company is pursuing Phase II proof of concept studies under an active IND in the US and additional mechanistic clinical trials OUS.

Topical-Lingual Neural Signaling:

  • Topical Lingual (T-L) delivery bypasses systemic exposure common to all other means of delivery
  • Gila plans to develop multiple natural hormones via the multiple of high-density lingual receptors to provide comprehensive weight loss & management, and to treat type 2 diabetes and associated metabolic disorders

Topical-Lingual PYY:

  • Previous attempts by others to deliver PYY have failed due to nausea: unavoidable with systemic exposure
  • Gila provides the only known viable PYY delivery

Obesity Epidemic

Worldwide

United States

Worldwide Metabolic Disorders

Type 2 Diabetes

NAFLD

Chronic Kidney Disease

NASH

Cardiovascular Disease

SOURCES: 1. Center for Disease Control (CDC); 2. World Health Organization (WHO) 7.8bn people: 13% with obesity, 9% with diabetes